Fedor Heidenreich

Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

Ludwig Kappos, Amit Bar‐Or, Bruce Cree et al. · The Lancet · 2018 · 896 citations

Neurological Disorder, Clinical Neurology, Clinical Trials +9

Benefit of interferon β-1a on MSFC progression in secondary progressive MS

Jeffrey A. Cohen, Gary Cutter, Jill S. Fischer et al. · Neurology · 2002 · 403 citations

A point mutation in PTPRC is associated with the development of multiple sclerosis

Marc Jacobsen, Dorothee Schweer, Andreas Ziegler et al. · Nature Genetics · 2000 · 195 citations

Genetic Disorder, Medicine, Genetics +7

Contrast letter acuity as a visual component for the Multiple Sclerosis Functional Composite

Laura J. Balcer, Monika Baier, J. A. Cohen et al. · Neurology · 2003 · 189 citations

An accurate fully automated panel of plasma biomarkers for Alzheimer's disease

Sebastian Palmqvist, Erik Stomrud, Nicholas Cullen et al. · Alzheimer s & Dementia · 2022 · 159 citations · Full text